Jul 13, 2020 11:47 JST
Source: Eisai
|
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Research Activities Commence
TOKYO, Jul 13, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization. This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. In this project, Eisai aims at creating a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) through industry-academia-government collaboration, using its in-house discovered new oral Toll-Like Receptor (TLR) 7/8 inhibitor E6742.
SLE is a designated intractable autoimmune disease that causes various organ disorders involving the disorders of the skin and the musculoskeletal system. The estimated number of patients with SLE in Japan is 60,000 to 100,000. In particular, the onset of SLE appears more commonly in females in their 20s to 40s. As such, SLE is a disease with extremely high unmet medical needs. The current treatment mainstays are corticosteroids, hydroxychloroquine, and an immunosuppressant, but the development of new effective therapeutic agents with fewer side effects is desired.
According to the latest research findings, it has been reported that TLR7/8, a member of the TLRs-family of receptors, is associated with the pathogenesis of SLE, suggesting the possibility of controlling SLE by a TLR7/8-specific inhibitor. E6742 has selective and potent inhibitory activity against TLR7/8, and is expected to potentially become a new therapeutic agent for SLE.
In this project, Eisai will conduct the clinical development of E6742. In addition, the top-class research institutes for TLR and SLE research in Japan (University of Occupational and Environmental Health, Japan; Osaka University; Hokkaido University; Tohoku University) and Eisai's research subsidiary KAN Research Institute will carry out an academic-driven clinical observational research in order to clarify the pathogenesis of SLE.
By creating new innovation based on industry-academia-government collaboration and fulfilling unmet medical needs, Eisai will contribute to increasing the benefits of patients and their families.
About CiCLE
AMED's CiCLE is a grant program to promote the establishment of infrastructure (including human resources) to respond to medical needs and the creation of an environment for open innovation and venture development based on industry-academia-government collaboration.
About TLR and E6742
TLRs are receptors of the innate immune system, and recognize the specific molecular structure of pathogens. It is considered that TLR initiated activation of the innate immune system plays a critical role in eliminating pathogens, causing an inflammatory reaction or an antiviral response. TLRs constitute a family of various receptors. According to the latest research findings, it has been reported that TLR7/8, a member of the TLRs-family of receptors, is associated with the pathogenesis of SLE, suggesting the possibility of controlling SLE disease by a TLR7/8-specific inhibitor. E6742 is a highly active and selective TLR7/8 inhibitor created by Eisai's former Andover Research Laboratories in the United States. In non-clinical studies, E6742 has been shown to suppress TLR7/8 stimulation induced cytokine production specifically and potently, and in addition, in a mouse model with SLE-like pathological conditions, it has been confirmed that E6742 is effective in improving the pathology. Furthermore, a Phase I single dose clinical trial of E6742 has been completed in the United States.
Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease induced by antibodies that causes various organ disorders involving disorders of the skin and the musculoskeletal system. About 90% of patients with SLE are female, especially among 20-40 years old, and the estimated number of patients is 60,000 to 100,000 in Japan. The cause of SLE is unknown, and it is designated as an intractable autoimmune disease in Japan (Designation 49)1. In Japan, the global standard drug for SLE, hydroxychloroquine, was approved in 2015 and the biologic berimumab was approved as a treatment for SLE in 2017, respectively. However, SLE is a disease with huge unmet medical needs, with great expectations for the establishment of new treatment options.
Activity of AMED's CiCLE in Eisai
As a key initiative for industry-academia-government collaboration in which Eisai is participating, a project aiming to identify and verify novel drug discovery target candidates linked to the development of next-generation treatments and preventative medicines for dementia at the Eisai-Keio Innovation Lab for Dementia (EKID) (Location: Keio University Shinanomachi campus) has also been selected by AMED for the CiCLE program. In addition, a research project represented by KAN on nucleic acid drug discovery research using novel nucleic acid synthesis and delivery technologies, and an initiative originated in Japan to develop biologics and new biomarkers for Crohn's disease represented by Eisai's gastrointestinal disease business subsidiary EA Pharma Co., Ltd. have been respectively selected by AMED for CiCLE.
(1) Japan Intractable Diseases Information Center - systemic lupus erythematosus (SLE) (Designation 49): https://www.nanbyou.or.jp/entry/53(New Window) (Available in Japanese only)
About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com
Contact:Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
Latest Release
MITSUBISHI MOTORS Announces Production, Sales and Export Figures for August 2020
Sep 29, 2020 17:30 JST
| 
DENSO's NaviBridge, a Smartphone Application Designed to Send Searched Locations from Phones to Car Navigation Systems, Compatible with Over 1,000 GPS
Sep 29, 2020 17:22 JST
| 
Mazda Production and Sales Results for August 2020
Sep 29, 2020 17:07 JST
| 
Toyota's Global Sales in August Recover to Approximately 90% Year-on-Year Sales Recovering at a Faster Pace than Expected
Sep 29, 2020 14:36 JST
| 
Hitachi ABB Power Grids Acquires Pioneer Solutions LLC and Strengthens Energy Portfolio Management
Sep 29, 2020 12:24 JST
|
MITSUBISHI L200 Won Russia Car of the Year 2020 and Two Other Prestigious Awards
Sep 28, 2020 15:26 JST
| 
Honda Exhibits World Premiere of "Honda SUV e:concept" at the 2020 Beijing International Automotive Exhibition (Auto China 2020)
Sep 28, 2020 10:22 JST
|
Hitachi ABB Power Grids Energizes First Phase of Raigarh-Pugalur 800 kV UHVDC Transmission Link
Sep 28, 2020 09:18 JST
| 
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
Sep 28, 2020 09:04 JST
| 
Mitsubishi Power Expands Promotion of Proprietary Boiler Smart Inspection Service Package for Managing Power Generation Facilities
Sep 25, 2020 16:15 JST
|
Hitachi Begins Testing of 5G Powered Industrial IoT Solutions at its Silicon Valley Research Center in California, USA
Sep 25, 2020 15:44 JST
|
MITSUBISHI MOTORS Rolls Out the OUTLANDER PHEV in Puerto Rico
Sep 25, 2020 14:29 JST
| 
NEC Face Recognition Engine Provides Highly Accurate Results Even When Face Masks are Worn
Sep 25, 2020 13:48 JST
| 
Showa Denko Announces Merger between Consolidated Subsidiaries and Change of Company Name
Sep 24, 2020 19:00 JST
| 
Fujitsu and SNP Announce Global Platinum Partnership Agreement -- Accelerating SAP S/4HANA Conversion Business with Advanced Data Transformation Technologies
Sep 24, 2020 14:55 JST
|
Hitachi ABB Power Grids to Invest Over $100 Million in Strategic Realignment of Global High-Voltage Switchgear Business
Sep 24, 2020 13:30 JST
| 
Mitsubishi Corporation: Use of CO2 in Concrete / Partnership with Blue Planet Systems Corporation
Sep 23, 2020 16:00 JST
|
Hitachi Hosts "Hitachi Social Innovation Forum 2020 TOKYO ONLINE"
Sep 23, 2020 14:22 JST
|
Hitachi ABB Power Grids Launches Open and Scalable Ecosystem for Digitalization of Transformers
Sep 23, 2020 10:38 JST
|
Fujitsu to Deliver New Supercomputer System for Canon
Sep 23, 2020 10:25 JST
|
More Latest Release >>
|